SCHEMBL204011

SCHEMBL204011

Cc1cc(O)c(F)c(C)c1-c1cccc(C=O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.46
TRIM24 O15164 2/20 0.40
TRIM33 Q9UPN9 2/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
DYRK1A Q13627 2/20 0.38
DYRK2 Q92630 2/20 0.38
DYRK1B Q9Y463 2/20 0.38
AR P10275 3/20 0.35
KDM4E B2RXH2 1/20 0.35
PTGS2 P35354 1/20 0.35
RAB9A P51151 1/20 0.35
UNG P13051 1/20 0.35
ALDH1A1 P00352 3/20 0.34
NPY5R Q15761 1/20 0.34
ERN1 O75460 2/20 0.33
AOX1 Q06278 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL204537 0.83 BRD4 (0.46) BRD4TRIM24TRIM33CA12CA1
SCHEMBL205804 0.79 BRD4 (0.53) BRD4TRIM24TRIM33CA12CA1
SCHEMBL16347706 0.77 BRD4 (0.46) BRD4TRIM24TRIM33CA12CA1
SCHEMBL15125801 0.75 CNR2 (0.45) ALDH1A1CNR2
SCHEMBL205798 0.75 BRD4 (0.53) BRD4TRIM24TRIM33CA12CA1
SCHEMBL1974835 0.75 BRD4 (0.55) BRD4TRIM24TRIM33CA12CA1
SCHEMBL31118369 0.74 BRD4 (0.50) BRD4TRIM24TRIM33CA12CA1
SCHEMBL1745297 0.74 BRD4 (0.58) BRD4TRIM24TRIM33CA12CA1
SCHEMBL206282 0.73 BRD4 (0.50) BRD4TRIM24TRIM33CA12CA1
SCHEMBL3936527 0.72 BRD4 (0.49) BRD4TRIM24TRIM33CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2803664-B1 TETRAHYDROBENZOFURANE DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF DIABETES JIANGSU HENGRUI MEDICINE CO (CN) 2018-11-21 EP disclosed
US-9139548-B2 Polycyclic derivatives, preparation process and pharmaceutical use thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2015-09-22 US disclosed
US-9139548-B2 Polycyclic derivatives, preparation process and pharmaceutical use thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2015-09-22 US disclosed
US-9139548-B2 Polycyclic derivatives, preparation process and pharmaceutical use thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2015-09-22 US disclosed
US-20150005282-A1 POLYCYCLIC DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2015-01-01 US disclosed
US-20150005282-A1 POLYCYCLIC DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2015-01-01 US disclosed
US-20150005282-A1 POLYCYCLIC DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2015-01-01 US disclosed
EP-2803664-A1 POLYCYCLIC DERIVATIVES, PREPARATION METHOD AND MEDICAL USES THEREOF Jiangsu Hengrui Medicine Co. Ltd. (CN) 2014-11-19 EP disclosed
EP-2803664-A1 POLYCYCLIC DERIVATIVES, PREPARATION METHOD AND MEDICAL USES THEREOF Jiangsu Hengrui Medicine Co. Ltd. (CN) 2014-11-19 EP disclosed
EP-2743268-A2 Fused cyclic compounds as GPR40 receptor modulators Takeda Pharmaceutical Company Limited (JP) 2014-06-18 EP disclosed
US-20100197761-A1 Fused cyclic compounds YASUMA TSUNEO 2010-08-05 US disclosed
US-20100197761-A1 Fused cyclic compounds YASUMA TSUNEO 2010-08-05 US disclosed
US-20100197761-A1 Fused cyclic compounds YASUMA TSUNEO 2010-08-05 US disclosed
US-7732626-B2 Fused cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-08 US disclosed
US-7732626-B2 Fused cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-08 US disclosed
US-7732626-B2 Fused cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-08 US disclosed
US-20100004312-A1 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed
US-20100004312-A1 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed
US-20100004312-A1 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed
WO-2008001931-A2 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004312-A1 FUSED CYCLIC COMPOUNDS GPR119, GLP1R, GPR65 BRD4 994/4885TRIM24 3254/4885TRIM33 3866/4885
US-20100197761-A1 Fused cyclic compounds GPR119, GLP1R, GPR65 BRD4 994/4885TRIM24 3254/4885TRIM33 3866/4885
US-20150005282-A1 POLYCYCLIC DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF GPR119, GPR55, GPR65 BRD4 2138/4885TRIM24 3086/4885TRIM33 2400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.